VEGF inhibitors (bevacizumab) can improve CAR-T therapy by reducing immunosuppressive myeloid cell infiltration and normalizing tumor vasculature, while TKIs (cabozantinib) enhance anti-tumor immune responses when combined with ICIs (Truffaux et al., 2015). This evidence concerns the gene VEGFA and neoplasm.